Kestra Medical Stock Slides as Wider-Than-Expected Loss Overshadows Revenue Growth

Shares of Kestra Medical Technologies fell sharply in after-hours trading on Monday after the company reported a first-quarter loss that was substantially wider than Wall Street forecasts, raising investor concerns about its path to profitability.

The medical technology firm's stock dropped 9.6% to $21.75 in post-market activity following the release of its fiscal 2027 first-quarter results.

Earnings Miss Weighs on Shares

For the quarter ending July 31, 2026, Kestra posted an adjusted loss of -$0.75 per share, missing the analyst consensus estimate of -$0.63. This represented a significant deterioration from the -$0.50 per share loss recorded in the same period a year prior.

The company's GAAP net loss also widened considerably to $44.1 million from $25.8 million year-over-year, driven by a steep climb in operating expenses. The adjusted EBITDA loss deepened to -$24.0 million, amplifying concerns about mounting costs.

Ad

Strong Revenue and Guidance Not Enough

Despite the earnings miss, Kestra delivered strong top-line performance and an optimistic outlook. Key positive metrics from the report include:

• Revenue: Grew 60% year-over-year to $31.0 million.
• Gross Margin: Expanded to 56.5%, up from 45.7% in the prior-year quarter.
• Full-Year Guidance: Management raised its fiscal 2027 revenue forecast to $141 million from a previous target of $137 million, implying 48% annual growth.

However, this strong operational performance was not enough to offset worries over the widening losses. Investor sentiment was further dampened by reports of significant insider selling, with 37 open-market sales versus only one purchase in the last six months. Additionally, short interest in the stock has risen to nearly 11% of the float, signaling increased bearish sentiment from the market.